This page is updated frequently with new Diabetes-related patent applications.
520+ Diabetes-related patent PDFs
|Antagonists of slc38a9 and their use in therapy|
The present invention relates to an antagonist or modulator of slc38a9 for use in treating a disease associated with mtorc1 activation, like a proliferative disease (e.g. A cancerous disease or benign proliferative disease), a metabolic disorder, a disorder of the immune system, a disorder causing premature aging, an ophthalmic disorder or a neurological disorder.
Cemm - Forschungzentrum Fuer Molekulare Medizin Gmbh
|Neo-islets comprising stem and islet cells and treatment of diabetes mellitus therewith|
Described are neo-islets comprising: a) dedifferentiated islet cells and mesenchymal and/or adipose stem cells; or b) redifferentiated islet cells and mesenchymal and/or adipose stem cells where the cells have been treated so as to facilitate redifferentiation. Further described herein are methods of generating neo-islets, the methods comprising: culturing a) dedifferentiated islet cells and mesenchymal and/or adipose stem cells; or b) redifferentiated islet cells and mesenchymal and/or adipose stem cells; on a surface that promotes the formation of cell clusters.
|Compositions and methods for the treatment of diabetes and pre-diabetes|
The invention relates to the compounds and compositions of formula i, formula ii, formula iii, formula iv, formula v, formula vi or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of dipeptidyl peptidase-4 inhibitor and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
|Compositions and methods for regulating pancreatic beta cell function using adipsin|
The present invention provides compositions and methods for regulating pancreatic beta cell function through modulation of adipsin activity and/or expression. Also provided are methods for preventing, treating, diagnosing, and prognosing metabolic disorders, such as diabetes, in a subject through modulation or detection of adipsin activity and/or expression..
Dana-farber Cancer Institute, Inc.
|Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders|
The present invention is directed to the use of co-therapy comprising administration of canagliflozin and phentermine for the treatment of obesity and obesity related disorders. More particularly, the present invention is directed to co-therapy for treating obesity, for promoting weight loss and/or for suppressing appetite; for treating, delaying, slowing the progression of and/or preventing metabolic disorders (including for example type 2 diabetes mellitus); for treating, delaying, slowing the progression of and/or preventing renal or fatty liver disorders (including for example nash, nafld, etc.); for treating, delaying, slowing the progression of and/or preventing sleep disorders (including for example sleep apnea); for providing cardiovascular protection; for treating, delaying, slowing the progression of and/or preventing cardiovascular events (including major adverse cardiac events (mace) such as myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal or non-fatal cerebrovascular accident, peripheral arteriopathy, aortic events, hospitalization due to congestive heart failure, etc.); and/or for extending or prolonging life span..
Janssen Pharmaceutica Nv
|Ciclopirox for use in modulation of glucose homeostasis|
Modulation of glucose homeostasis by administration of ciclopirox (6-cyclohexyl-1-hydroxy-4-methylpyridin-2(1h)-one) is described. Methods can be utilized in treatment of conditions that involve loss of glucose homeostasis, such as diabetes, and in one particular embodiment type ii diabetes.
University Of South Carolina
|Method and system to derive glycemic patterns from clustering of glucose data|
Described are methods and systems for determining clusters of glucose data that can be utilized to provide insights to the person with diabetes, such as, for example, when a certain number of measurements during a predetermined time period is less than a predetermined threshold so that the subject is notified that the number of glucose measurements is less than optimum for management of diabetes.. .
|Novel insulin analogs and use thereof|
The present invention relates to a novel insulin analog, and more specifically, to an insulin analog with an improved in vitro effect compared with native insulin, a nucleic acid encoding the same, an expression vector including the nucleic acid, a transformant introduced with the expression vector, a method of producing the insulin analog from the transformant, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition.. .
Hanmi Pharm. Co., Ltd.
The invention relates to a peptide analogue comprising at least residues 2-13 of seq id no: 1 and further comprising at least a substitution or modification at residue 13 of seq id no: 1. The invention also relates to a pharmaceutical composition comprising the peptide analogue of the present invention and methods of treatment of diabetes, stimulating insulin release and moderating blood glucose excursions comprising administering the peptide analogue of the present invention to a patient in need thereof..
University Of Ulster
|Bicyclic derivatives and pharmaceutical composition including the same|
The present invention relates to a novel bicyclic derivative that has an inhibitory activity against sodium-glucose linked transporters (sglts) present in the intestines and kidneys, or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, and a pharmaceutical composition including the same as an active ingredient, which effectively inhibit the sglt activity, and thus can be used as a therapeutic agent to treat diseases caused by hyperglycemia, such as diabetes including insulin-dependent diabetes (type i diabetes mellitus) and non-insulin-dependent diabetes (type ii diabetes mellitus), diabetic complications, and obesity.. .
Hanmi Pharm. Co., Ltd.
Controlled inhaler for distributing inhalant according to inhalation velocity
An inhaler is provided that includes a controller, a driver, an atomizer and one or more sensors for detecting information about a velocity of inhalation of a user of the inhaler. The controller is configured to dispense an inhalant from the inhaler during an inhalation of the user based on information about the velocity of inhalation of the user.
Incube Labs, Llc
Composition for imaging atherosclerosis and diagnosing atherosclerosis by using same
The present disclosure relates to a composition for imaging atherosclerosis and a method for diagnosing atherosclerosis using the same. The composition for imaging atherosclerosis according to the present disclosure shows excellent atherosclerosis diagnosis accuracy, enables diagnosis of atherosclerosis even for a person with diseases of glucose metabolism such as diabetes and enables effective diagnosis even for atherosclerosis occurring in the brain and heart.
Seoul National University R&db Foundation
Compositions containing alpha-1-antitrypsin and methods for use
Methods and compositions for treating patients (e.g., patients who are insulin resistant, patients who have diabetes, or are at risk for developing diabetes) are disclosed herein. The methods can include administration of an al antitrypsin (aat) polypeptide or an agent, such as a nucleic acid molecule or organic compound, that promotes the expression or activity of α1-antitrypsin..
The General Hospital Corporation
Treatment of diabetes using g-csf
E. Exposing the patient to a stem cell proliferation agent for a third treatment period; whereby the patient's blood glucose level begins trending lower subsequent to initiation of treatment and continues to trend lower after active treatment has ended..
Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
The invention relates to the identification of new therapeutic methods for the fgf21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. Insulin receptor mutation disorders (insr disorders) and/or autoimmune insulin receptor disorders (type b insulin resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (nafld), and other metabolic disorders, and various lipodystrophies such as hiv-haart induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients..
Non-reducing end unsaturated mannuronic acid oligosaccharides and compositions containing same as active ingredient
Disclosed is a non-reducing end unsaturated mannuronic acid oligosaccharide having a molecular weight of 100-3000 da, which is obtained by lysing polymannuronate as a substrate with alginate lyase, and provided are: a non-reducing end unsaturated mannuronic acid oligosaccharide; and pharmaceutical compositions for alleviating, preventing, or treating obesity, diabetes, and climacteric syndrome, and probiotics for promoting intestinal beneficial bacteria, the compositions and probiotics containing, as an active ingredient, the non-reducing end unsaturated mannuronic acid oligosaccharide, so that the antiobesity and antidiabetic effects, estrogen activity, and intestinal microflora controlling effect of the non-reducing end unsaturated mannuronic acid oligosaccharides are remarkably excellent as compared with non-reducing end saturated mannuronic acid oligosaccharides.. .
Industry Foundation Of Chonnam National University
Activated soy pod fiber
The present disclosure encompasses, among other things, compositions and methods of enhancing glyceollin content of soybean tissue as well as methods of large-scale production of soybean tissues comprising elevated glyceollin content. The present disclosure further encompasses administration of food products comprising glyceollins in the treatment or prevention (i.e., delay of onset) of overweight, obesity, prediabetes, diabetes, ibd, and gastrointestinal dysbiosis..
Microblome Therapeutics Llc
Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, huntington's disease, epilepsy, multiple sclerosis (ms), lupus, type-1 and type-2 diabetes, maturity onset diabetes of the young (mody), myasthenia gravis (mg), rheumatoid arthritis (ra), graves' disease, guillain-barré syndrome (gbs), metabolic syndrome, muscular dystrophy or duchenne muscular dystrophy (dmd), severe burns, aging, amyotrophic lateral sclerosis (als), friedreich's ataxia, batten disease, alzheimer's disease, optic neuritis, leber's hereditary optic neuropathy (lhon), autism, rett syndrome, batten disease, angelman's syndrome, leigh disease, fragile-x syndrome, depression, parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous bdnf expression with dnp treatment to protect from neuromuscular dysfunction/disorders and/or neurodegeneration and/or muscle wasting. Dnp was administered to mice daily over a range of doses, and subsequently bdnf expression in the brain showed a dose dependent and non-linear increase in expression..
Mitochon Pharmaceuticals, Inc.
Double-acylated glp-1 derivatives
The invention relates to a derivative of a glp-1 analogue, which analogue comprises a first k residue at a position corresponding to position 27 of glp-1(7-37) (seq id no: 1); a second k residue at a position corresponding to position t of glp-1(7-37), where t is an integer in the range of 7-37 except 18 and 27; and a maximum of ten amino acid changes as compared to glp-1(7-37); wherein the first k residue is designated k27, and the second k residue is designated kt; which derivative comprises two albumin binding moieties attached to k27 and kt, respectively, via a linker, wherein the albumin binding moiety comprises a protracting moiety selected from hooc—(ch2)x—co— and hooc—c6h4—o—(ch2)y—co—; in which x is an integer in the range of 6-16, and y is an integer in the range of 3-17; wherein the linker comprises an element of the formula —nh—(ch2)2—(o—(ch2)2)k—o—(ch2)n—co—, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel glp-1 analogues.
Novo Nordisk A/s
Peptides hormone analogues derivable from preproglucagon
Peptide hormone analogues of the formula x-v are provided herein, wherein x is a glucagon analogue or a glp1 analogue, and v is a c-terminal extension amino acid sequence comprising at least four amino acid residues, at least three of said residues being his. Also provided herein are pharmaceutical compositions comprising said analogues, and methods of using said analogues for the treatment of conditions such as obesity and diabetes..
Imperial Innovations Limited
Phenyl c-glucoside derivative containing deoxyglucose structure, preparation method and use thereof
The present invention provides a phenyl c-glucoside derivative containing a deoxyglucose structure as represented by formula i, preparation method thereof, a pharmaceutical composition comprising the same, and uses thereof in the preparation of medicaments for treating diabetes, wherein substituents r1-r7 are as defined in the specification. The present invention also provides a method for synthesizing the phenyl c-glucoside derivative containing a deoxyglucose structure and an intermediate product.
Tianjin Institute Of Pharmaceutical Research
Heteroaromatic compounds and their use as dopamine d1 ligands
And pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating d1-mediated (or d1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, ad, pd, or pharmacotherapy therapy), adhd, impulsivity, compulsive gambling, overeating, autism spectrum disorder, mcl, age-related cognitive decline, dementia, rls, parkinson's disease, huntington's chorea, anxiety, depression, mdd, trd, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, sle, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.. .
Substituted pyridazines as prostacyclin receptor modulators
Cyclohexane derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
Arena Pharmaceuticals, Inc.
Method of using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions
A polyphenol derivative of the stilbenoid family, namely trans-3,5,4′-trihydroxybibenzyl, also known as dihydro-resveratrol, is disclosed as a remedial agent. In particular, the usage of dihydro-resveratrol as an anti-fibrotic agent in suppressing the activation of pancreatic stellate cells (pscs) is presented.
Hong Kong Baptist University
System, method, and computer readable medium for dynamic insulin sensitivity in diabetic pump users
A technique for treating diabetes that recognizes patient insulin sensitivity is a time-varying physiological parameter. The described techniques for treating diabetes include measuring interstitial fluid glucose concentration, reading insulin delivery data, determining patient insulin sensitivity based on the interstitial fluid glucose concentration and insulin delivery data, and a time-varying physiological parameter, and dispensing an insulin dose from an insulin delivery device based on the determined patient insulin sensitivity..
University Of Virginia Patent Foundation
Compositions and methods for treating diabetes
The present disclosure is a compound, a method of making the compound and method of using such compound preferably in the form of a dietary supplement that, when administered, is capable of treating prediabetes, diabetes, insulin resistance or metabolic syndrome. The unique combination of the composition is preferably administered orally.
Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer
Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.. .
The Board Of Regents Of The University Of Texas System
Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions
Method of using dopamine reuptake inhibitors, e.g., sydnonimine derivatives, for the management of diabetic symptoms and associated complications or conditions, such as hyperglycemia and diabetic neuropathy.. .
Caliper Life Sciences, Inc.
Ghrelin o-acyltransferase inhibitors
Small molecule ghrelin o-acyltransferase inhibitors found using an assay to detect ghrelin o-acyltransferase activity using an acrylodan-labeled peptide mimic of ghrelin that provides for high-throughput screening for ghrelin o-acyltransferase inhibitors and detection via high performance liquid chromatography. The newly discovered class of synthetic triterpenoids efficiently inhibits ghrelin acylation by goat and function as covalent reversible inhibitors of goat.
The present invention relates to pharmaceutical compositions comprising a solid dispersion of dapagliflozin and one or more pharmaceutically acceptable excipients, and processes for their preparation. It further relates to a method of treating diabetes using said pharmaceutical compositions..
Sun Pharmaceutical Industries Limited
Type 1 Diabetes
Human Embryonic Stem Cell
Embryonic Stem Cell
Follow us on Twitter
This listing is a sample listing of patent applications related to Diabetes for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Diabetes with additional patents listed. Browse our RSS directory or Search for other possible listings.